Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.
Article
PubMed
Google Scholar
Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C, Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer: Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002, 60 (3 Suppl 1): 1-6. 10.1016/S0090-4295(02)01559-5.
Article
PubMed
Google Scholar
Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma. J Clin Oncol. 1985, 3: 827-841.
CAS
PubMed
Google Scholar
Tannock IF, De Wit R, Berry WR, de Wit R, Eisenberger M, Tannock IF: Docetaxel plus Prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351: 1502-1512. 10.1056/NEJMoa040720.
Article
CAS
PubMed
Google Scholar
Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and Estramustine compared with Mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351: 1513-1520. 10.1056/NEJMoa041318.
Article
CAS
PubMed
Google Scholar
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB: Population pharmacokinetics/pharmacodinamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998, 16: 187-196.
CAS
PubMed
Google Scholar
Bournique B, Lemarie A: Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos. 2002, 30: 1149-1152. 10.1124/dmd.30.11.1149.
Article
CAS
PubMed
Google Scholar
Sissung TM, Price DK, Sparreboom A, Figg WD: Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006, 4: 135-150. 10.1158/1541-7786.MCR-05-0101.
Article
CAS
PubMed
Google Scholar
McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI: Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 2001, 62: 207-212. 10.1016/S0006-2952(01)00643-8.
Article
CAS
PubMed
Google Scholar
Martinez VG, O'Connor R, Liang Y, Clynes M: CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer. 2008, 98: 564-570. 10.1038/sj.bjc.6604195.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sissung TM, Danesi R, Price KM, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A: Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther. 2008, 1: 19-26. 10.1158/1535-7163.MCT-07-0557.
Article
Google Scholar
Landi MT, Bergen AW, Baccarelli A, Patterson DG, Grassman J, Ter-Minassian M, Mocarelli P, Caporaso N, Masten SA, Pesatori AC, Pittman GS, Bell DA: CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology. 2005, 207: 191-202. 10.1016/j.tox.2004.08.021.
Article
CAS
PubMed
Google Scholar
Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K: Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999, 20: 1607-1613. 10.1093/carcin/20.8.1607.
Article
CAS
PubMed
Google Scholar
McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, Ingelman-Sundberg M: Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys. 2000, 378: 175-181. 10.1006/abbi.2000.1808.
Article
CAS
PubMed
Google Scholar
Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T: Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol. 2005, 67: 435-443. 10.1124/mol.104.006056.
Article
CAS
PubMed
Google Scholar
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C: Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010, 9: 581-593. 10.1158/1535-7163.MCT-09-0665.
Article
CAS
PubMed
Google Scholar
Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF: Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics. 2000, 10: 761-766. 10.1097/00008571-200012000-00001.
Article
CAS
PubMed
Google Scholar
The SNP500Cancer Database. --- Either ISSN or Journal title must be supplied.. [http://snp500cancer.nci.nih.gov]
Herbst RS, Khuri FR: Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003, 29: 407-415. 10.1016/S0305-7372(03)00097-5.
Article
CAS
PubMed
Google Scholar
Rosell R, Felip E: Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol. 2001, 28 (4 Suppl 14): 37-44. 10.1016/S0093-7754(01)90058-2.
Article
CAS
PubMed
Google Scholar
Hitzl M, Drescher S, Van Der Kuip H, Schäffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001, 11: 293-298. 10.1097/00008571-200106000-00003.
Article
CAS
PubMed
Google Scholar
Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ: MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration. 2009, 78: 49-55. 10.1159/000158454.
Article
CAS
PubMed
Google Scholar
Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007, 25: 4528-4535. 10.1200/JCO.2006.10.4752.
Article
CAS
PubMed
Google Scholar
Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008, 14: 4543-4549. 10.1158/1078-0432.CCR-07-4230.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chaib H, Cockrell EK, Rubin MA, Macoska JA: Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia. 2001, 3: 43-52. 10.1038/sj.neo.7900126.
Article
CAS
PubMed
PubMed Central
Google Scholar
Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003, 64: 659-669. 10.1124/mol.64.3.659.
Article
CAS
PubMed
Google Scholar
Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S: The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010, 46: 517-525. 10.1016/j.ejca.2009.11.007.
Article
CAS
PubMed
Google Scholar
de Wit R: Chemotherapy in hormone-refractory prostate cancer. BJU Int. 2008, 101 (Suppl 2): 11-15. 10.1111/j.1464-410X.2007.07485.x.
Article
CAS
PubMed
Google Scholar
Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G: Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology. 2004, 63: 321-326. 10.1016/j.urology.2003.09.044.
Article
PubMed
Google Scholar
Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J Pharmacol Exp Ther. 2001, 296: 537-541.
CAS
PubMed
Google Scholar
D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA. 1994, 91: 3964-3968. 10.1073/pnas.91.9.3964.
Article
PubMed
PubMed Central
Google Scholar
Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T: Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics. 2000, 10: 343-353. 10.1097/00008571-200006000-00008.
Article
CAS
PubMed
Google Scholar
Brandi G, de Rosa F, Danesi R, Montini GC, Biasco G: Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?. Eur Urol. 2008, 54: 938-941. 10.1016/j.eururo.2008.07.029.
Article
CAS
PubMed
Google Scholar
Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007, 7: 362-365. 10.1038/sj.tpj.6500434.
Article
CAS
PubMed
Google Scholar